Table of Contents Author Guidelines Submit a Manuscript
Biochemistry Research International
Volume 2014, Article ID 703128, 5 pages
http://dx.doi.org/10.1155/2014/703128
Research Article

Roles of the Oxidative Stress and ADMA in the Development of Deep Venous Thrombosis

1School of Health, Bozok University, 66200 Yozgat, Turkey
2Department of Biochemistry, Yuzuncu Yil University Medical Faculty, 65080Van, Turkey
3Department of Medical Biology, Yuzuncu Yil University Medical Faculty, 65080 Van, Turkey
4Department of Cardiovascular Surgery, Bozok University Medical Faculty, 66200 Yozgat, Turkey

Received 23 December 2013; Revised 13 March 2014; Accepted 13 March 2014; Published 13 April 2014

Academic Editor: Tzi Bun Ng

Copyright © 2014 Meral Ekim et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. T. M. Hyers, “Venous thromboembolism,” The American Journal of Respiratory and Critical Care Medicine, vol. 159, no. 1, pp. 1–14, 1999. View at Google Scholar · View at Scopus
  2. C. T. Esmon, “Basic mechanisms and pathogenesis of venous thrombosis,” Blood Reviews, vol. 23, no. 5, pp. 225–229, 2009. View at Publisher · View at Google Scholar · View at Scopus
  3. J. A. López and J. Chen, “Pathophysiology of venous thrombosis,” Thrombosis Research, vol. 123, no. 4, pp. S30–S34, 2009. View at Publisher · View at Google Scholar · View at Scopus
  4. Y. Baykal, G. Özet, and F. Kocabalkan, “Venöz trombozla ilişkili risk faktörleri,” T-Klinik Journal of Medical Sciences, vol. 19, pp. 236–241, 1999. View at Google Scholar
  5. D. Balcı and S. Hazinedaroğlu, “Derin ven trombozu; epidemiyoloji, risk faktörleri, patogenez, komplikasyonlar,” Türkiye Klinikleri Cerrahi Dergisi, vol. 2, pp. 81–92, 2003. View at Google Scholar
  6. S. Demirci, M. R. Sekeroglu, T. Noyan et al., “The importance of oxidative stress in patients with chronic renal failure whose hypertension is treated with peritoneal dialysis,” Cell Biochemistry and Function, vol. 29, pp. 249–254, 2011. View at Google Scholar
  7. Z. S. Nedeljkovic, N. Gokce, and J. Loscalzo, “Mechanisms of oxidative stress and vascular dysfunction,” Postgraduate Medical Journal, vol. 79, no. 930, pp. 195–200, 2003. View at Publisher · View at Google Scholar · View at Scopus
  8. C. Kunsch and R. M. Medford, “Oxidative stress as a regulator of gene expression in the vasculature,” Circulation Research, vol. 85, no. 8, pp. 753–766, 1999. View at Google Scholar · View at Scopus
  9. J. P. Cooke, “Does ADMA cause endothelial dysfunction?” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 20, no. 9, pp. 2032–2037, 2000. View at Google Scholar · View at Scopus
  10. M. A. W. Broeders, G.-J. Tangelder, D. W. Slaaf, R. S. Reneman, and M. G. A. Oude Egbrink, “Endogenous nitric oxide protects against thromboembolism in venules but not in arterioles,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 18, no. 1, pp. 139–145, 1998. View at Google Scholar · View at Scopus
  11. R. H. Böger, “The emerging role of asymmetric dimethylarginine as a novel cardiovascular risk factor,” Cardiovascular Research, vol. 59, no. 4, pp. 824–833, 2003. View at Publisher · View at Google Scholar · View at Scopus
  12. J. P. Cooke, “ADMA: its role in vascular disease,” Vascular Medicine, vol. 10, no. 1, pp. S11–S17, 2005. View at Publisher · View at Google Scholar · View at Scopus
  13. L. Goth, “A simple method for determination of serum catalase activity and revision of reference range,” Clinica Chimica Acta, vol. 196, no. 2-3, pp. 143–151, 1991. View at Publisher · View at Google Scholar · View at Scopus
  14. P. A. Pleban, A. Munyani, and J. Beachum, “Determination of selenium concentration and glutathione peroxidase activity in plasma and erythrocytes,” Clinical Chemistry, vol. 28, no. 2, pp. 311–316, 1982. View at Google Scholar · View at Scopus
  15. M. S. Goel and S. L. Diamond, “Adhesion of normal erythrocytes at depressed venous shear rates to activated neutrophils, activated platelets, and fibrin polymerized from plasma,” Blood, vol. 100, no. 10, pp. 3797–3803, 2002. View at Publisher · View at Google Scholar · View at Scopus
  16. G. Re, C. Lanzarini, I. Vaona et al., “Systemically circulating oxidative species in human deep venous thrombosis,” European Journal of Emergency Medicine, vol. 5, no. 1, pp. 9–12, 1998. View at Google Scholar · View at Scopus
  17. V. Muzakova, R. Kandar, P. Vojtısek, J. Skalıcky, and Z. Cervınkova, “Selective antioxidant enzymes during ischemia/reperfusion in Myocardial Infarction,” Physiological Research, vol. 49, pp. 315–322, 2000. View at Google Scholar
  18. B. Voetsch, R. C. Jin, C. Bierl et al., “Role of promoter polymorphisms in the plasma glutathione peroxidase (GPx-3) gene as a risk factor for cerebral venous thrombosis,” Stroke, vol. 39, no. 2, pp. 303–307, 2008. View at Publisher · View at Google Scholar · View at Scopus
  19. B. Ozbay and H. Dulger, “Lipid peroxidation and antioxidant enzymes in Turkish population: relation to age, gender, exercise, and smoking,” Tohoku Journal of Experimental Medicine, vol. 197, no. 2, pp. 119–124, 2002. View at Publisher · View at Google Scholar · View at Scopus
  20. B. Buijsse, D.-H. Lee, L. Steffen et al., “Low serum glutathione peroxidase activity is associated with increased cardiovascular mortality in individuals with low HDLc’s,” PLoS ONE, vol. 7, no. 6, Article ID e38901, 2012. View at Google Scholar
  21. J. E. Freedman, B. Frel, G. N. Welch, and J. Loscalzo, “Glutathione peroxidase potentiates the inhibition of platelet function by S-nitrosothiols,” Journal of Clinical Investigation, vol. 96, no. 1, pp. 394–400, 1995. View at Google Scholar · View at Scopus
  22. G. Kenet, J. Freedman, B. Shenkman et al., “Plasma glutathione peroxidase deficiency and platelet insensitivity to nitric oxide in children with familial stroke,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 19, no. 8, pp. 2017–2023, 1999. View at Google Scholar · View at Scopus
  23. J. E. Freedman, J. Loscalzo, S. E. Benoit, C. R. Valeri, M. R. Barnard, and A. D. Michelson, “Decreased platelet inhibition by nitric oxide in two brothers with a history of arterial thrombosis,” Journal of Clinical Investigation, vol. 97, no. 4, pp. 979–987, 1996. View at Google Scholar · View at Scopus
  24. C. Vadseth, J. M. Souza, L. Thomson et al., “Pro-thrombotic state induced by post-translational modification of fibrinogen by reactive nitrogen species,” Journal of Biological Chemistry, vol. 279, no. 10, pp. 8820–8826, 2004. View at Publisher · View at Google Scholar · View at Scopus
  25. J. T. Kielstein, D. Tsikas, and D. Fliser, “Effects of asymmetric dimethylarginine (ADMA) infusion in humans,” European Journal of Clinical Pharmacology, vol. 62, no. 13, pp. 39–44, 2006. View at Publisher · View at Google Scholar · View at Scopus
  26. S. R. Lentz, “Mechanisms of homocysteine-induced atherothrombosis,” Journal of Thrombosis and Haemostasis, vol. 3, no. 8, pp. 1646–1654, 2005. View at Publisher · View at Google Scholar · View at Scopus
  27. N. Skoro-Sajer, F. Mittermayer, A. Panzenboeck et al., “Asymmetric dimethylarginine is increased in chronic thromboembolic pulmonary hypertension,” The American Journal of Respiratory and Critical Care Medicine, vol. 176, no. 11, pp. 1154–1160, 2007. View at Publisher · View at Google Scholar · View at Scopus
  28. J. T. Kielstein, S. M. Bode-Böger, G. Hesse et al., “Asymmetrical dimethylarginine in idiopathic pulmonary arterial hypertension,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 25, no. 7, pp. 1414–1418, 2005. View at Publisher · View at Google Scholar · View at Scopus
  29. D. G. Haider, R. A. Bucek, M. Reiter et al., “The cardiovascular risk marker asymmetrical dimethylarginine is not affected by venous thromboembolism,” Translational Research, vol. 148, no. 1, pp. 26–29, 2006. View at Publisher · View at Google Scholar · View at Scopus
  30. G. Beutel, R. Perthel, M. Suntharalingam, S. M. Bode-Boger, J. Martens-LObenhoffer, and J. T. Kieelstein, “Effect of chronic elevated asymmetrc dimethylarginine (ADMA) levels on granulopoiesis,” Annals of Hematology, vol. 92, pp. 505–508, 2013. View at Google Scholar
  31. A. Undas, J. Brozek, and A. Szczeklik, “Homocysteine and thrombosis: from basic science to clinical evidence,” Thrombosis and Haemostasis, vol. 94, no. 5, pp. 907–915, 2005. View at Publisher · View at Google Scholar · View at Scopus
  32. S. Omar, I. B. Ghorbel, H. Feki et al., “Hyperhomocysteinemia is associated with deep venous thrombosis of the lower extremities in Tunisian patients,” Clinical Biochemistry, vol. 40, no. 1-2, pp. 41–45, 2007. View at Publisher · View at Google Scholar · View at Scopus
  33. M. C. Stühlinger and O. Stanger, “Asymmetric Dimethyl-L-Arginine (ADMA): a possible link between homocyst(e)ine and endothelial dysfunction,” Current Drug Metabolism, vol. 6, no. 1, pp. 3–14, 2005. View at Publisher · View at Google Scholar · View at Scopus
  34. G. Hron, R. Lombardi, S. Eichinger, A. Lecchi, P. A. Kyrie, and M. Cattaneo, “Low vitamin B6 levels and the risk of recurrent venous thromboembolism,” Haematologica, vol. 92, no. 9, pp. 1250–1253, 2007. View at Publisher · View at Google Scholar · View at Scopus
  35. M. Cattaneo, R. Lombardi, A. Lecchi, P. Bucciarelli, and P. M. Mannucci, “Low plasma levels of vitamin B6 are independently associated with a heightened risk of deep-vein thrombosis,” Circulation, vol. 104, no. 20, pp. 2442–2446, 2001. View at Google Scholar · View at Scopus
  36. K. Zhou, R. Zhao, Z. Geng et al., “Association between B-group vitamins and venous thrombosis: systematic review and meta-analysis of epidemiological studies,” Journal of Thrombosis and Thrombolysis, vol. 34, pp. 459–467, 2012. View at Google Scholar